Novogen Limited is a drug discovery company. It has offices both in Australia and the USA.
Novogen is a public company, dual-listed on both the ASX ('NRT') and Nasdaq ('NVGN').
The Company owns two proprietary first-in-class drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs), both small molecule cytotoxics.
These technologies target new drug targets with broad therapeutic potential across the fields of cancer, regenerative medicine, neurodegenerative diseases, musculodegenerative diseases, lysosomal storage diseases, and autoimmune diseases.
Novogen has a pipeline of 4 oncology candidates that currently are pre-clinical and are scheduled to enter first-in-man studies across a wide range of cancers commencing 4Q15.
updated 30th March, 2015
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |